EN DE

Radiant Innovation (3373) Fair Value & Analysis

Healthcare · TW · Market cap 845M TWD

RI Radiant Innovation 3373 · TWO
Price16.75 TWD
Fair Value12.23 TWD
Upside-27.0%
Quality44/100
Watch Radiant Innovation for free, get notified when fair value or trend changes. Watch for free

Risks

!Trades 27% ABOVE our fair value of 12.23 TWD
!Weak Growth
!Loss-making · -13.7% net margin
!negative free cash flow
Weak Growth
Loss-making · -13.7% net margin
negative free cash flow
Trails peers (3/9)
Narrow moat 10/100
Evidence: Low Range 8.07 TWD – 15.29 TWD Share as image

Fair value as of: Aug 13, 2026

From 3 valuation models · updated 9 days ago

Share price +0.3% over the past month.

Below-average quality, and screening another 27% overvalued on our models.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price sits above even our optimistic bull case (15.29 TWD). The favourable scenario is already priced in.
  • Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • A fairly wide model range (8.07 TWD to 15.29 TWD) leaves room in how you read the outcome.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

69.47 TWD 15.85 TWD Fair Value 12.23 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 15.85 TWD – 69.47 TWD · fair‑value band 8.07 TWD – 15.29 TWD · the 16.75 TWD price screens above the 12.23 TWD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Radiant Innovation (3373) currently trades at 16.75 TWD, while our model-based Fair Value estimate is 12.23 TWD, implying the stock looks roughly 27.0% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Radiant Innovation generated revenue of 389M TWD at a net margin of -13.7%. Revenue grew 2.0% year over year. It earns a return on equity of -6.5%. Fundamentals as of Aug 13, 2026

Our scenario range runs from 8.07 TWD (bear case) to 15.29 TWD (bull case); at 16.75 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -27%, 3373 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Gordon GGM 7.06 TWD 7.61 TWD 8.43 TWD 70
DDM Multi-Stage 7.06 TWD 8.41 TWD 10.14 TWD 61
NCAV (Graham) 8.33 TWD 11.17 TWD 16.67 TWD 50
All 3 models by family
Dividend Discount
Gordon GGM 7.06 TWD 7.61 TWD 8.43 TWD 70
DDM Multi-Stage 7.06 TWD 8.41 TWD 10.14 TWD 61
Asset-Based
NCAV (Graham) 8.33 TWD 11.17 TWD 16.67 TWD 50

Widest divergence: Asset-Based (11.17 TWD) versus Dividend Discount (7.61 TWD). Highest evidence: Gordon GGM (70).

Notify me when 3373 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 389M TWD
Revenue growth (YoY) +2.0%
Net margin -13.7%
Return on equity -6.5%
Free cash flow −5.2M TWD FY2025
Operating margin -22.3%
More key figures
EPS (TTM) -1.27 TWD
EPS growth (YoY) -74.4%

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 44/100

Of which business quality 44 · Market factors (momentum, volatility) 43

Profitability 8
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 88
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 65
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Radiant Innovation Inc. engages in the design and development of infrared technology products in Taiwan, Japan, and Germany. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; and CO2 monitors.

Full company description

Radiant Innovation Inc. engages in the design and development of infrared technology products in Taiwan, Japan, and Germany. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; and CO2 monitors. The company also offers industrial infrared thermometers, infrared precision thermal imagers, infrared precision gas monitors and other components. Radiant Innovation Inc. was founded in 1989 and is headquartered in Hsinchu City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Radiant Innovation reported revenue of 388M TWD in FY2025 versus 985M TWD in FY2021, a compound −20.8%/yr. Reported net income was −60.4M TWD in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
388M TWD
Latest YoY
−7.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−11.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−31.7%
Avg. growth/yr (8Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.2%
Revenue −20.8%/yr
FY21 985M TWD
FY22 565M TWD
FY23 418M TWD
FY24 421M TWD
FY25 388M TWD
Net income
FY21 112M TWD
FY22 28.7M TWD
FY23 −48.8M TWD
FY24 −28.6M TWD
FY25 −60.4M TWD

3373 screens 27% overvalued. Compare with Abbott Laboratories, →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Radiant Innovation Fair Value". https://www.fairvalue-calculator.com/stock/3373

Peer Group

Medical Devices · 362 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 44 · Below median
Fair Value upside −27% · Above median
Return on assets -4% · Below median
Net margin (TTM) -14% · Bottom 25%
Operating margin (TTM) -22% · Bottom 25%
Revenue growth 2% · Below median
Dividend yield (TTM) 5.4% · Top 25%

Valuation Multiples vs Medical Devices median · lower = cheaper

P/S (TTM) 0.07× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE10 · sector 31
PAST0 · sector 3
HEALTH0 · sector 97
DIVIDEND100 · sector 34

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $110.91 $74.79 -33%
Stryker Corporation SYK $327.70 $186.28 -43%
Medtronic plc MDT $90.76 $65.57 -28%
Boston Scientific Corporation BSX $50.37 $38.44 -24%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 -2%
Shanghai United Imaging Healthcare Co 688271 ¥110.50 ¥43.60 -61%
Demant A/S DEMANT kr 289.60 kr 161.17 -44%
Getinge AB GETIB kr 240.60 kr 192.14 -20%
Sectra AB SECTB kr 280.00 kr 66.81 -76%
CLASSYS Inc 214150 39,700 KRW 20,415 KRW -49%

Compare Radiant Innovation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Evidence & backtest 34 years, survivorship-adjusted Financial calculators DCF, Graham, PEG and more

Frequently asked questions

Is Radiant Innovation (3373) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 12.23 TWD versus a price of 16.75 TWD, about −27% (overvalued).
What is the fair value of 3373?
Our model-based fair value for Radiant Innovation is 12.23 TWD (as of Aug 13, 2026), built from audited fundamentals. The current price: 16.75 TWD.
What is the quality score of 3373?
Radiant Innovation has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Radiant Innovation (3373)?
Radiant Innovation reported trailing-twelve-month revenue of about 389M TWD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 3373?
The net profit margin of Radiant Innovation is about -13.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Radiant Innovation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.